Adding Daratumumab to VRd Boosts MRD Negativity in Transplant-Ineligible Myeloma
Adding daratumumab to bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved minimal residual disease (MRD)-negativity and progression-free survival in newly diagnosed multiple myeloma patients ineligible for stem cell transplant, according to the CEPHEUS trial. The MRD-negative CR rate increased by 50% with daratumumab-augmented therapy (D-VRd), leading to superior progression-free survival at 54 months.
Highlighted Terms
Related News
Adding daratumumab to bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved minimal residual disease (MRD)-negativity and progression-free survival in newly diagnosed multiple myeloma patients ineligible for stem cell transplant, according to the CEPHEUS trial. The MRD-negative CR rate increased by 50% with daratumumab-augmented therapy (D-VRd), leading to superior progression-free survival at 54 months.